Eli Lilly (LLY)
934.60
+83.39 (9.80%)
NYSE · Last Trade: Apr 30th, 10:45 PM EDT
Detailed Quote
| Previous Close | 851.21 |
|---|---|
| Open | 898.78 |
| Bid | 932.48 |
| Ask | 933.00 |
| Day's Range | 896.80 - 945.50 |
| 52 Week Range | 623.78 - 1,133.95 |
| Volume | 8,236,718 |
| Market Cap | 894.02B |
| PE Ratio (TTM) | 40.72 |
| EPS (TTM) | 22.9 |
| Dividend & Yield | 6.920 (0.74%) |
| 1 Month Average Volume | 3,208,843 |
Chart
About Eli Lilly (LLY)
Eli Lilly is a global pharmaceutical company dedicated to discovering, developing, manufacturing, and marketing innovative medicines that address some of the world's most challenging health issues. The company focuses on areas such as diabetes, oncology, immunology, and neurodegenerative diseases, providing a wide range of treatments designed to improve patient outcomes and quality of life. Eli Lilly is committed to scientific advancement and works collaboratively with healthcare professionals and researchers to bring new therapies and solutions to market, ensuring access to life-saving medications for patients around the globe. Read More
News & Press Releases
Via Benzinga · April 30, 2026
Thursday's session: top gainers and losers in the S&P500 indexchartmill.com
Via Chartmill · April 30, 2026
In today's session, there are S&P500 stocks with remarkable trading volume.chartmill.com
Via Chartmill · April 30, 2026
Eli Lilly (LLY) Q1 2026 Earnings Transcript
Via The Motley Fool · April 30, 2026
Eli Lilly (NYSE:LLY) Shatters Q1 Expectations with Blowout Earnings Beatchartmill.com
Via Chartmill · April 30, 2026
Exploring the top movers within the S&P500 index during today's session.chartmill.com
Via Chartmill · April 30, 2026

GLP-1 drugs turned Lilly into a powerhouse. Now it's time to write the next chapter -- in cancer.
Via The Motley Fool · April 30, 2026
Eli Lilly beats Q1 estimates, lifts 2026 outlook as Mounjaro and Zepbound demand offsets pricing pressure and drives strong revenue growth.
Via Benzinga · April 30, 2026
These S&P500 stocks are gapping in today's sessionchartmill.com
Via Chartmill · April 30, 2026
Eli Lilly stock popped early Thursday after the drugmaker crushed first-quarter sales forecasts and hiked its 2026 guidance.
Via Investor's Business Daily · April 30, 2026
Discover the top S&P500 movers in Thursday's pre-market session.chartmill.com
Via Chartmill · April 30, 2026
Global pharmaceutical company Eli Lilly (NYSE:LLY) reported Q1 CY2026 results topping the market’s revenue expectations, with sales up 55.5% year on year to ...
Via StockStory · April 30, 2026
The biotech's candidate may treat a great number of illnesses that have one thing in common.
Via The Motley Fool · April 30, 2026
Eli Lilly & Co. (LLY) will release Q1 earnings on April 30. Analysts expect $6.79/share, up from $3.34/share last year. LLY down 2.6% on Wed.
Via Benzinga · April 30, 2026
Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) is a late-stage life sciences company focused on advancing the development of anti-inflammatory and anti-fibrotic therapies for heart disease. The CRDL lead small-molecule drug candidate, CardiolRx™, modulates inflammasome pathway activation, an intracellular process known to play an important role in the development and progression of inflammation and fibrosis associated with pericarditis, myocarditis, and heart failure.
Via Get News · April 29, 2026
Global pharmaceutical company Eli Lilly (NYSE:LLY) will be reporting results this Thursday before market hours. Here’s what to expect. Eli Lilly beat analyst...
Via StockStory · April 28, 2026

And he may be right.
Via The Motley Fool · April 28, 2026
What Happened? Shares of personal wellness company WeightWatchers (NASDAQ:WW) fell 5.3% in the afternoon session after the company announced its intention to...
Via StockStory · April 28, 2026
Via MarketBeat · April 28, 2026
The drugmaker is getting on the AI train in ways that could move the needle down the road.
Via The Motley Fool · April 27, 2026
Eli Lilly has more to offer than some investors realize.
Via The Motley Fool · April 27, 2026
Hims & Hers stock rallied on Friday on a major regulatory update and bullish analyst note. Here’s how high HIMS shares could realistically fly through the end of 2026.
Via Barchart.com · April 27, 2026
Eli Lilly shares sink as data shows Foundayo trailing Novo’s oral Wegovy. But there’s reason to consider buying LLY shares on the dip today.
Via Barchart.com · April 27, 2026
Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) is a late-stage life sciences company focused on advancing the development of anti-inflammatory and anti-fibrotic therapies for heart disease. The CRDL lead small-molecule drug candidate, CardiolRx™, modulates inflammasome pathway activation, an intracellular process known to play an important role in the development and progression of inflammation and fibrosis associated with pericarditis, myocarditis, and heart failure.
Via Get News · April 27, 2026
This pharma stock is cheap for a reason.
Via The Motley Fool · April 27, 2026
